domperidone has been researched along with Scleroderma, Systemic in 4 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 6.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| "Systemic sclerosis (SSc) patients often become refractory to proton pump inhibitors (PPI)-a standard treatment for gastroesophageal reflux disease (GERD)-and intolerant to PPI in combination with domperidone." | 4.31 | Cost-effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients. ( Chaiyarit, J; Foocharoen, C; Kingkaew, P; Mahakkanukrauh, A; Manasirisuk, W; Sangchan, A; Suwannaroj, S; Teerawattananon, Y, 2023) |
| "Twice-daily dosing of proton pump inhibitor (PPI), the standard therapy for gastro-oesophageal reflux disease (GERD), is an effective therapy for GERD in SSc." | 2.84 | Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. ( Chunlertrith, K; Foocharoen, C; Mahakkanukrauh, A; Mairiang, P; Namvijit, S; Nanagara, R; Suwannaroj, S; Wantha, O, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Foocharoen, C | 2 |
| Kingkaew, P | 1 |
| Teerawattananon, Y | 1 |
| Mahakkanukrauh, A | 2 |
| Suwannaroj, S | 2 |
| Manasirisuk, W | 1 |
| Chaiyarit, J | 1 |
| Sangchan, A | 1 |
| Chunlertrith, K | 1 |
| Mairiang, P | 1 |
| Namvijit, S | 1 |
| Wantha, O | 1 |
| Nanagara, R | 1 |
| Wollheim, FA | 1 |
| Akesson, A | 1 |
| Kobayashi, T | 1 |
| Kobayashi, M | 1 |
| Naka, M | 1 |
| Nakajima, K | 1 |
| Momose, A | 1 |
| Toi, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of Domperidone Versus Alginic Acid Add on Omeprazole Therapy in Omeprazole Resistance Gastroesophageal Reflux in Systemic Sclerosis[NCT01878526] | Phase 3 | 80 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Unit scale 0-48 was applied for an outcome measurement of the frequency of symptoms. The unit scale 0 was no symptom and scale 48 was usual symptom of GERD. The changing of the frequency of symptoms was the changing of the unit scale before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 4.6 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 4.7 |
VAS scale 0-100 was applied for an outcome measurement of the quality of life. The VAS scale 0 was the worst quality of life and scale 100 was the best quality of life. The changing of the quality of life was the changing of VAS of quality of life before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 75.7 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 76.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of regurgitation. The VAS scale 0 was no symptoms of regurgitation and scale 100 was a maximum symptom of regurgitation. The changing of the severity of regurgitation was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 24.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 23.1 |
VAS scale 0-100 was applied for an outcome measurement of the severity of heart burn. The VAS scale 0 was no symptoms of heart burn and scale 100 was a maximum symptom of heart burn. The changing of the severity of heart burn was the changing of VAS before and after treatment. (NCT01878526)
Timeframe: 8 weeks
| Intervention | VAS (100) (Mean) |
|---|---|
| Omeprazole Plus Alginic Acid and Placebo of Domperidone | 17.9 |
| Omeprazole Plus Domperidone and Placebo of Alginic Acid | 17.2 |
(NCT01878526)
Timeframe: 4 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Overall Systemic Sclerosis With GERD (Before Randomization) | 59 |
1 trial available for domperidone and Scleroderma, Systemic
| Article | Year |
|---|---|
Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial.
Topics: Adult; Aged; Alginates; Antiemetics; Domperidone; Drug Therapy, Combination; Female; Gastroesophagea | 2017 |
3 other studies available for domperidone and Scleroderma, Systemic
| Article | Year |
|---|---|
Cost-effectiveness of alginic acid in combination with proton pump inhibitor for the treatment of gastroesophageal reflux disease in systemic sclerosis patients.
Topics: Alginic Acid; Cost-Benefit Analysis; Domperidone; Gastroesophageal Reflux; Humans; Infant, Newborn; | 2023 |
Management of intestinal involvement in systemic sclerosis.
Topics: Domperidone; Dopamine Antagonists; Gastrointestinal Agents; Gastroparesis; Humans; Indoles; Metoclop | 2007 |
Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis.
Topics: Adult; Combined Modality Therapy; Dinoprost; Domperidone; Female; Gastrointestinal Motility; Humans; | 1993 |